Drug
Enicepatide
Enicepatide: highest development phase Phase 3, developed by Roche. 5 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Roche
Trials
| Drug | Phase | Indication |
|---|---|---|
| Enicepatide NCT07351058 | Phase 3 | Obesity or Overweight |
| Enicepatide NCT07351045 | Phase 3 | Obesity or Overweight |
| Enicepatide NCT07670416 | Phase 3 | Obesity |
| Enicepatide NCT07918846 | Phase 3 | Overweight |
| Enicepatide NCT07889648 | Phase 3 | Type 2 Diabetes Mellitus |
Latest
No recent events.
Follow Enicepatide on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.